Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

As obesity rates in the United States soar, insurance companies, including Medicaid and Medicare, are facing financial ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a shortage of the brand-name drug has ended – which means compounding of the ...

The FDA said Eli Lilly’s weight-loss drugs were no longer in shortage on Oct. 2, preventing pharmacies from making cheaper ...

Yep, you can actually be thrown in jail for buying certain weight loss drugs on Facebook (or any other social media platform, ...

A turbulent series of events around the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around ...

Scientists from Yale and other institutions have discovered that tirzepatide, a drug approved to treat type 2 diabetes, may also be highly effective for weight loss in people with obesity. This ...

The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from Fullerton Wellness had an unidentified "black particulate" floating in it.

Online health platforms continue to advertise access to copycat versions of blockbuster weight-loss drugs Wegovy and Zepbound ...

Tirzepatide is the active ingredient in the U.S. firm's diabetes drug Mounjaro, and weight-loss drug Zepbound ... competition ...